GROINSS-V III; Groningen International Study on Sentinel node in Vulvar cancer III – a prospective phase 2 treatment trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508722-99-00

Enrollment

Registered

2024-03-12

Start date

2020-11-19

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvar cancer

Brief summary

Groin recurrences

Detailed description

Treatment related morbidity, Disease-specific survival, Patient reported quality of life

Interventions

DRUGCisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie

DRUGCarboplatin Accord Healthcare 10 mg/ml concentraat voor oplossing voor infusie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Groin recurrences	—

Secondary

Measure	Time frame
Treatment related morbidity, Disease-specific survival, Patient reported quality of life	—

Countries

Belgium, France, Netherlands, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026